FDA Brief

Warning letters Drugs

FDA warning letter to

Legacy Pharmaceutical Packaging LLC

High riskIssued Oct 3, 2022Posted Oct 11, 2022Division of Pharmaceutical Quality Operations III

Legacy Pharmaceutical Packaging, a drug repackager, was cited for CGMP violations and insanitary conditions after foreign tablets and floor-picked tablets were found.

What happened

FDA inspected the drug repackaging facility from April 12 to April 27, 2022. It found inadequate investigations of foreign tablets in bottles of repackaged drugs, records filled out for work not performed, and a production video showing an operator picking tablets off the floor and placing them into the feed hopper. The firm opened an event for the floor-tablet incident only after FDA raised it, and FDA found the firm's May 17, 2022, response inadequate.

What FDA found

  1. The firm failed to thoroughly investigate unexplained discrepancies or batch failures, including foreign tablets found in bottles of its repackaged drugs.

    21 CFR 211.192
  2. The firm did not extend mix-up investigations to other batches on the same packaging line or in the facility, despite potential equipment design, cleaning, and line-clearance problems.

    21 CFR 211.192
  3. The firm failed to address records being filled out for work not performed, such as a filler cleaning checklist.

    21 CFR 211.192
  4. An operator was observed picking individual tablets up off the floor and placing them directly into the feed hopper during active filling.

    Section 501(a)(2)(A), FD&C Act; 21 CFR 211.113(a)
  5. The firm opened an event only after FDA raised the floor-tablet incident but did not evaluate the affected lot, assure floor-contact material would not re-enter batches, or extend the review to other batches.

    21 CFR 211.192

What FDA wants

FDA tells the firm to correct violations promptly and to respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks for independent evaluations and action plans for packaging and labeling, investigations, cleaning, and product-quality and patient-safety risks in U.S. distribution.

Who should pay attention

  • companies whose finished drugs are repackaged or relabeled by this firm
  • brands and distributors that use contract packagers
  • quality teams responsible for packaging-line clearance and investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk